MORF Overview
Upcoming Projects (MORF)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MORF)
-
Discussing Morphic's MORF-057 and the data on the endoscopic improvement in patients with ulcerative colitis recently published at the United European Gastroenterology Week Conference
Ticker: MORF
Executed On: Oct 03, 2023 at 11:00 AM EDT -
Discussing Morphic's MORF-057, an oral α4β7 integrin, for treatment in adults with moderate to severe ulcerative colitis
Ticker: MORF
Executed On: Jun 16, 2023 at 11:30 AM EDT -
Another View: Discussing Morphic's MORF-057 (oral a4b7 integrin) and its potential in ulcerative colitis ahead of the Phase 2a readout
Ticker: MORF
Executed On: Feb 15, 2023 at 12:30 PM EST -
Discussing new therapies in development for Ulcerative Colitis with a focus on MORF-057 from Morphic and PRA023 from Prometheus
Tickers: MORF, RXDX
Executed On: Jan 23, 2023 at 11:00 AM EST -
A Second Perspective: Discussing a4b7 integrin blocking in moderate to severe ulcerative colitis: Looking at 1st gen PTG-100 and MORF-057
Tickers: MORF, PTGX, TAK
Executed On: Feb 04, 2022 at 11:00 AM EST -
A discussion around a4b7 integrin blocking in moderate to severe ulcerative colitis: Looking at 1st gen PTG-100 and MORF-057
Tickers: MORF, PTGX, TAK
Executed On: Feb 01, 2022 at 02:00 PM EST
Expired Projects (MORF)
-
Discussing the UC landscape and how upcoming new therapies could affect that
Tickers: ROIV, MORF, TEVA
Execute By: Oct 27, 2023
Upcoming & Overdue Catalysts (MORF)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (MORF)
Strategic Initiatives (MORF)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
